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Natural killer cells (NKs) are important effectors of the innate immune
system, with marked antitumor activity. Imaging NK trafficking in vivo
may be relevant to following up the efficacy of new therapeutic
approaches aiming at increasing tumor-infiltrating NKs (TINKs). The
specific aims of present study were to efficiently target NKs using
a 99mTc-anti-CD56 and to image human NK trafficking in SCID mice
bearing human cancer. Methods: The anti-CD56 monoclonal anti-
body (mAb) was radiolabeled with 99mTc, and in vitro quality controls
were performed to test labeling efficiency, stability, and binding affinity
to CD56. In vivo biodistribution was determined by injecting 5.5 MBq
(104 ng) of radiolabeled antibody in the tail vein of SCID mice, which
were then sacrificed at 1, 3, 6, and 24 h after injection. Targeting
experiments were performed on 2 groups of SCID mice inoculated
subcutaneously with increasing numbers of human NKs in the right
thigh (from 2.5 · 106 to 40 · 106) and human granulocytes (CD56−)
or anaplastic thyroid cancer (ARO) cells in the contralateral thigh
as control. TINK trafficking imaging was achieved by injecting
5.5 MBq of 99mTc-anti-CD56 mAb in SCID mice bearing ARO tumor
xenografts in the right thigh, 24 h after being reconstituted with
105, 106, or 107 human NKs. Results: Anti-CD56 mAb was radiola-
beled, achieving a radiochemical purity of more than 97% and a spe-
cific activity of 3,700 MBq/mg and retaining biochemical integrity and
binding activity. In vivo studies revealed physiologic uptake in the
liver and kidneys. Targeting experiments confirmed the specificity
of labeled antibody to CD561 cells. Human NK cells injected in
CD1 nude mice accumulated in the ARO tumors within 24 h and were
imaged as early as 3 h after intravenous administration of 99mTc-
anti-CD56. Conclusion: 99mTc-anti-CD56 is a promising tool for in
vivo imaging of TINK cell trafficking.
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Besides surgery, radiation, and chemotherapy, our own immune
system has a key role against tumors. Recent scientific advances
have demonstrated its importance and potential in oncology. In-
deed, both innate and adaptive immunity cells are involved in the
immune surveillance process that prevents tumor development either
by releasing cytokines or by mediating a long-lived, antigen-specific
response. However, such mechanisms are often inhibited by tumor
cells capable of establishing a suitable microenvironment to sustain
their proliferation (1).
In the last 20 years, many new therapeutic strategies aimed at
increasing host response against tumors have been developed. These
include cytokines, monoclonal antibodies (mAbs), vaccines, adop-
tive cell transfers, and Toll-like receptor agonists (2–4). In particular,
natural killer cells (NKs) are a subset of lymphocyte with great
cytotoxic potential. Approximately 90% of peripheral blood and
spleen NKs are CD56dimCD161 and possess high cytotoxic activity,
whereas CD56brightCD162 cells have mainly an immune-regulatory
role (5). Under particular stimuli, NKs are able to kill certain targets,
including tumor cells, even without any prior immunization. Interest
in tumor-infiltrating NKs (TINKs) increased after publication of
several studies that correlated the presence of NKs with tumor prog-
nosis (6). High levels of TINKs are associated with good prognosis
in patients affected by cancer (7–9). Given the importance of TINKs
in the response against tumors, many companies are developing
drugs that can increase the number and efficacy of TINKs.
In this context, imaging NK trafficking in vivo may be relevant to
following up the efficacy of such novel therapeutic approaches.
Several attempts to image NKs have been made in the past few years
by different groups using direct labeling strategies that involve
purifying cells from peripheral blood, radiolabeling with 111In-oxine,
and readministering to patients (10,11). This approach has limitations
such as cell manipulation in culture and cell-function impairment after
ex vivo labeling. Several studies reported that 111In-oxine was toxic to
cells, leading to improper migration into target organs (12,13).
Thus, we investigated a novel approach for in vivo cell labeling
using a mAb that binds to CD56 antigen expressed on the surface
of human NKs (14). The use of such a radiopharmaceutical may
allow imaging of NKs directly in vivo, without the need for in
vitro manipulation. The aims of present study were to efficiently
radiolabel this mAb with 99mTc and to image human NK traffick-
ing in SCID mice bearing human cancer.
MATERIALS AND METHODS
Antibody
The C218 hybridoma cell line (producing the anti-CD56 mAb) was
kindly provided by Dr. A. Moretta (Institute Gaslini, Italy) (15). Hy-
bridoma cells were cultured in RPMI medium supplemented with 5%
fetal calf serum in a miniPERM bioreactor (Sarsted). After 8 d of
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culture, the medium was collected and clarified by centrifugation at
2,000 rpm for 10 min. The mAb was purified from hybridoma superna-
tant using protein-G–based affinity chromatography (Thermo-Scientific).
The column was equilibrated with 10 volumes of binding buffer (0.1 M
phosphate, 0.15 M NaCl) before the supernatant was loaded. Nonbound
serum components were washed away with 10 volumes of binding
buffer. The mAb was then eluted with 5 volumes of acidic elution buffer
(glycine-HCl, 0.1 M; pH 2.7), and small fractions of solution that passed
from the column were collected and subjected to spectrofluorimetric
analysis. Fractions with an optical density of more than 0.1 at 280 nm
were pooled and additionally purified through gel filtration, using a dextran
desalting column (Thermo-Scientific).
Cell Lines and NK Purification
The anaplastic thyroid cancer cell line (ARO) was cultured in high-
glucose Dulbecco modified Eagle medium (Gibco) supplemented with
fetal calf serum, 10%; penicillin/streptomycin (penicillin G, 10,000 U,
and streptomycin, 10 mg), 10 mL/L; amphotericin B (250 mg/mL), 10
mL/L; and L-glutamine, 1% (16). NKs were obtained from the blood of
healthy donors. Healthy donors’ peripheral blood mononuclear cells
(4 · 105 cells) were isolated by Lymphoprep (Stemcell Technologies)
gradient centrifugation and then cocultured for 10 d with irradiated
(30 Gy) Epstein-Barr virus–transformed B-cell line RPMI 8866 (105
cells) at 37C as previously described (17,18). After 10 d, the cells were
collected and phenotypically characterized through immunofluorescence
using anti-CD16 (3G8; BD-Biosciences), anti-CD56 (BD-Biosciences),
and anti-CD3 (BD-Biosciences) mAb and analyzed by flow cytometry
(BD-Biosciences). On day 10 the cell population was routinely greater
than 90% CD561CD161CD32; when purity was less than 90%, con-
taminant T-cells were eliminated by immunomagnetic negative selection
with anti-CD3 mAb to obtain a purity greater than 95%. Human
granulocytes were isolated from healthy donors by Percoll (GE Health-
care) gradient centrifugation as previously described (19).
Labeling of Anti-CD56 mAb with 99mTc
Briefly, 1 mg of lyophilized mAb was resuspended in 500 mL of
distilled water, and this solution was purified by size-exclusion chroma-
tography using a G-25 Sephadex PD10 column (GE Healthcare) and
nitrogen-purged phosphate-buffered saline (PBS) as eluent (20 mL). In-
direct labeling of anti-CD56 mAb was performed by conjugation of the
mAb with the heterobifunctional linker S-HYNIC (succinimidyl-6-hydra-
zinonicotinate hydrochloride) (SoluLink). The chelator (100 mM in dime-
thylformamide) was added at different molar ratios (from 20:1 to 50:1) to
a solution of antibody (20 mM) in 100 mM sodium phosphate/150 mM
NaCl buffer solution, pH 7.6–8.0. The mixture was purified by G-25
Sephadex PD10 column chromatography using nitrogen-purged cold
PBS (pH 7.4) as eluent. The number of HYNIC groups bound per mole-
cule of antibody was determined by molar substitution ratio assay. Briefly,
2 mL of conjugated anti-CD56 mAb were added to 18 mL of a 0.5 mM
solution of 2-sulfobenzaldehyde in 0.1 M 2-(N-morpholino)ethanesulfonic
acid buffer, pH 5.0, and incubated at room temperature for 2 h. After 2 h,
the absorbance at 345 nm of each reaction was measured with a spectro-
photometer and the number of HYNIC groups per molecule was calculated
as indicated in the SoluLink data sheet. To efficiently label the mAb–S-
HYNIC complex with 99mTc, to minimize the percentage of colloid for-
mation, and to optimize the influence of the amount of coligand on the
labeling efficiency, titrations of tricine (Sigma-Aldrich Chemicals; from 1
to 200 mg/mL in PBS) and SnCl2 (Sigma-Aldrich Chemicals; from 1 to
10 mg/mL in 0.1 M HCl) were performed with mAb–HYNIC complex
(25 mg) in 1 M sodium acetate (pH 5.5), using different amounts of freshly
eluted 99mTcO42 (100 mL) while keeping a constant reaction volume.
In Vitro Quality Controls of 99mTc-Anti-CD56 mAb
Quality controls were performed using instant thin-layer chroma-
tography–silica gel strips (VWR International) as described elsewhere
(20). The stability of the labeled antibody was measured in human
serum and 0.9% NaCl solution at 37C up to 24 h. For this purpose, 2
aliquots of 100 mL of 99mTc-anti-CD56 mAb were incubated with
900 mL of fresh human blood serum and with 900 mL of saline solu-
tion at 37C. The percentages of free 99mTc and antibody-bound ra-
dioactivity were measured at 1, 3, 6, and 24 h by instant thin-layer
chromatography–silica gel. In addition, a cysteine challenge assay was
performed to check the in vitro stability of the radiolabeled antibody.
99mTc-anti-CD56 mAb was incubated at 37C for 60 min at different
cysteine:mAb molar ratios, which ranged from 500:1 at the highest
cysteine concentration to zero in the absence of cysteine. At the end of
the incubation time, each reaction mixture was evaluated by instant
thin-layer chromatography–silica gel as described above. This exper-
iment was repeated in triplicates. Possible modifications induced by
the labeling procedure on anti-CD56 mAb were tested by sodium
dodecyl sulphate–polyacrylamide gel electrophoresis under nonreduc-
ing conditions, according to the method of Laemmli (21). Proteins
were visualized by staining the gels with Coomassie brilliant blue
(Pierce). Radioactivity associated with each band was determined
using a linear scanner (Bioscan Inc.). This experiment was per-
formed after 3 different labelings.
Immunoreactive Fraction Assay
The immunoreactive fraction assay was performed using a constant
concentration of radiolabeled mAb and serial dilutions of NKs
according to a published method (20). Cells were washed 3 times in PBS
and resuspended in a solution of cold 1% bovine serum albumin in PBS
(BSA/PBS). Radiolabeled mAb at a constant concentration (50 ng/mL)
in 1% BSA/PBS was added to different amounts of cells (final concen-
tration ranging from 1 · 106 to 0.08 · 106 cells/mL) in triplicates with
or without an excess of unlabeled antibody (100-fold molar excess).
Cells were incubated for 2 h at 4C and then washed twice with 500 mL
of cold 1% BSA/PBS before cell-associated radioactivity was counted
in a single-well g counter (Gammatom). Data were plotted as a double
inverse plot of the applied radiolabeled antibody over the specific bind-
ing, as a function of the inverse cell concentration. In this plot, the
origin of the abscissa represents infinite cell concentration, that is,
conditions of infinite antigen excess.
Uptake/Retention Assay (LigandTracer Assay)
Real-time measurements of cellular uptake and retention were
performed 3 times after different labelings, using a rotating radio-
immunoassay in a LigandTracer instrument (Ridgeview Instruments
AB) (22).
In a typical experiment, CD561 NKs (5 · 106) are resuspended in
1 mL of PBS and plated into fibronectin-coated plastic circular Petri
dishes and activated with 0.20 M N-ethyl-N9-(dimethylaminopropyl)
carbodiimide and 0.05 M N-hydroxysuccinimide. Each dish is then
incubated with cells and placed in the LigandTracer during a continu-
ous rotation of 1 h, to allow release of weakly attached cells. After
a single gentle wash, the cell dish is ready for measurement. Radio-
labeled mAb (0.7 nM) in pH 7.4 PBS supplemented with 7% cell
culture medium devoid of fetal calf serum is then added.
When the radiolabeled antibody binds to the cells, a detector placed
over the elevated part of the dish registers the cell-bound activity each
time the cells pass through the detector. By following the activity over
time, a real-time binding curve is obtained, using LigandTracer software,
version 1.1. Data are exported and analyzed with GraphPad software to
determine the dissociation constant.
In Vivo Biodistribution and Cell Targeting
For animal experiments, the institutional and national guide for the
care and use of laboratory animals was followed. For in vivo
biodistribution studies, 5.5 MBq (100 mL) of labeled anti-CD56 were
injected in the tail vein of 12 SCID mice and static planar posterior
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images were acquired using a high-resolution portable mini g camera
(23) at 1, 3, 6, and 24 h under light ether anesthesia. At the end of each
imaging point, 3 mice were sacrificed and major organs were collected
and counted in a single-well g counter. Time–activity curves in organs
were created for both in vitro and ex vivo data. For cell-targeting
studies, 2 groups of 24 SCID mice were subcutaneously injected in
the right thigh with increasing numbers (from 2.5 · 106 to 40 · 106)
of human CD561 NKs mixed with Matrigel (BD-Biosciences). In the
contralateral thigh of both groups, CD562 cells (ARO or human gran-
ulocytes) were injected as a negative control. After 1 h, 5.5 MBq of
99mTc-anti-CD56 were injected in the tail vein and planar posterior
images were acquired at 1, 3, 6, and 24 h.
Kinetic Studies of NK Infiltration in Tumors
To investigate the kinetics of NK infiltration in our xenograft
model, ARO cells from a male donor (XY genotype) mixed with
Matrigel were injected subcutaneously in the right thigh of 18 male
SCID mice (XY genotype). After tumor growth, 106 NKs from
a female donor (XX genotype) were injected in the tail vein. After
3 h, 3 mice were sacrificed and tumors were collected, formalin-
fixed, and paraffin-embedded. The same procedure was repeated
at 6, 12, 24, 48, and 72 h. Histologic analysis were performed at
each time point, including hematoxylin and eosin staining of sec-
tions, immunohistochemistry, and fluorescent in situ hybridization
(FISH) for the Y chromosome, allowing us to differentiate exoge-
nous human TINKs (XX genotype) from endogenous TINKs and
ARO cells (XY genotype). Immunoperoxidase staining with an
anti-CD57 mAb—revealed with DAB after a secondary antibody
incubation—was performed to identify CD571 TINKs. CD57 was
chosen as an NK marker to avoid any interference from injected
anti-CD56.
Imaging of TINKs in SCID Mice with ARO Tumors
Imaging of exogenous human TINKs was performed on 4 groups of
SCID mice (n 5 12) bearing an ARO tumor xenograft in the right
thigh. Three groups received 105, 106, and 107 human NKs, whereas
the fourth group was used as a negative control. After 24 h (as de-
termined from previous experiments), 5.5 MBq of 99mTc-anti-CD56
were injected in the tail vein of each mouse, and planar posterior
images were acquired by a high-resolution portable mini g camera
at 1, 3, 6, and 24 h after injection. After the last time point, the mice
were sacrificed for organ counting and histology.
RESULTS
Labeling and Quality Control of Anti-CD56 mAb
Molar substitution ratio analysis of HYNIC-conjugated mAb
revealed the presence of 9.1, 18, and 23.5 molecules of chelator per
molecule of antibody, when conjugated with a 20:1, 30:1, and 50:1
HYNIC:mAb ratio, respectively. A ratio of 30:1 was selected as the
formulation of choice since no modification of binding activity was
observed. Optimization of 99mTc labeling of HYNIC–mAb conju-
gate (25 mg of mAb; 30:1 HYNIC:mAb ratio; tricine, 55.8 mM;
SnCl2, 170 mM; 92 MBq; 10-min incubation at room tempera-
ture) gave a radiochemical purity of more than 97% after purifica-
tion by size-exclusion chromatography. The specific activity was
3,700 MBq/mg. Radiolabeled anti-CD56 mAb was stable in both
saline and human serum up to 24 h (.90%). The cysteine challenge
assay demonstrated moderate stability up to a 200-fold molar excess
of cysteine (supplemental data, available at http://jnm.snmjournals.
org). Sodium dodecyl sulphate–polyacrylamide gel electrophoresis
analysis showed no significant differences between the native and
radiolabeled anti-CD56 mAb (supplemental data). Native, conju-
gated, and radiolabeled mAb showed a band of approximately 150
kDa (i.e., molecular weight of complete mAb). However, a small
band of more than 250 kDa was also present in both lanes and could
be ascribed to dimers of the complete mAb, but the radioactivity was
associated only with the band corresponding to the intact mAb.
In Vitro Binding Experiments
The immunoreactive fraction assay data demonstrated a closely
linear relationship of total applied/specific binding as a function of
the inverse cell concentration. Unspecific binding was negligible,
and 76.9% (SD 5 63.5, SEM 5 1.73) of the radiolabeled mAb
was immunoreactive (Fig. 1). LigandTracer experiments showed
that the radiolabeled mAb was able to bind to NKs over time,
reaching a plateau at between 1 and 2 h. After replacement of
the radioactive medium with PBS, 99mTc-anti-CD56 was strongly
retained on the cell surface, with a slow off-rate (Fig. 2). A dis-
sociation constant of 1.7 · 10210 (SD 5 60.02 · 10210, SEM 5
0.0153 · 10210) was calculated by averaging 3 different experi-
ments. At the end of these experiments, all cells were viable (as
assessed by trypan blue exclusion), thus indicating that at least
until 33 h the 99mTc-mAb was not toxic to NKs.
In Vivo Biodistribution and Cell Targeting
In vivo biodistribution studies, summarized in Figure 3A, showed
a high circulating activity up to 24 h, with uptake occurring pre-
dominantly in the liver and, to a lesser extent, in the kidney. Blood
and liver showed the highest percentage injected dose per gram at
1 h, whereas at 24 h the highest activity was detected in the spleen
(Fig. 3A). Cell-targeting experiments demonstrated the possibility
of imaging as little as 2.5 · 106 NKs in a volume of 300 mL, with
a target-to-background (T/B) ratio of 1.8 (SD 5 60.1, SEM 5
0.0577) at 24 h. Animals injected with more than 107 NKs showed
a T/B ratio up to 4 at 24 h (Fig. 4).
Kinetic Studies of NK Cell Infiltration in Tumors
Studies of NK kinetics in vivo demonstrated that they were able
to infiltrate tumors as early as 3 h after injection, with a slight in-
crement over time and no contamination of host NKs as shown by
FISH analysis (Fig. 5; supplemental data). The most severe in-
filtration was between 12 and 24 h, whereas after 24 h the tumor
started to show necrotic areas induced by NK killing of tumor
FIGURE 1. Double inverse plot of data obtained by immunoreactive
fraction assay of radiolabeled 99mTc-anti-CD56 mAb. Each point repre-
sents mean of 3 different experiments, and error bars represent SD
(y 5 56.88x 1 1.33; R2 5 0.997).
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cells. We therefore selected 24 h as best time point for future
experiments.
Imaging of TINKs in SCID Mice with Implanted ARO Tumors
The radiopharmaceutical allowed clear visualization of tumor
xenografts with almost no signal from negative controls. The
highest uptake was detected at 24 h after injection, with a T/B
ratio of 6.02 that correlated with the number of CD561/CD571
TINKs as confirmed by immunohistochemistry studies (Fig. 6).
Moreover, the number of NKs positively correlated with the size
of the tumors (r2 5 0.89; P 5 0.001) and with the radioactivity
detected by ex vivo organ counting (r2 5 0.90; P 5 0.001) (Fig.
7). No correlation was found between the number of injected NK
cells and the number of TINKs in the tumor. Overall, larger tumors
were more infiltrated and showed more necrosis.
DISCUSSION
In the present study, we radiolabeled an anti-CD56 mAb as
a novel radiopharmaceutical to image TINKs. This approach could
be important in the development of novel cancer-immunotherapy
drugs aimed at increasing NK infiltration into tumors, to follow up
the efficacy of these drugs. Indeed, this approach could allow
researchers to monitor cell trafficking directly in vivo. Despite the
long half-life of mAbs, we chose 99mTc as the isotope because this
anti-CD56 showed high-affinity binding in vitro and gave good
visualization of TINKs in vivo within 3 and 24 h after intravenous
administration. The mAb was radiolabeled using a well-estab-
lished technique based on the use of S-HYNIC as a bifunctional
FIGURE 4. T/B ratios calculated in mice injected with increasing
amounts of CD561 NKs in right thigh and with same amounts of CD56−
control cells in left thigh. Mice were imaged at 1 h (white bar), 3 h (squared
bar), 6 h (dotted bar), and 24 h (black bar). Image of mouse injected with
106 NK was acquired 24 h after injection of 5.5 MBq of radiolabeled mAb.
FIGURE 3. Biodistribution of radiolabeled anti-CD56 mAb at 1, 3, 6,
and 24 h in normal mice. Data are percentage injected dose per organ
(A) and percentage injected dose per gram (B). Error bars denote SD.
FIGURE 5. (A and B) Hematoxylin- and eosin-stained low-power (A)
and high-power (B) fields showing tumor infiltrated by numerous lym-
phocytes. (C and D) Lymphocytic infiltrate was formed by NKs as dem-
onstrated by CD57 immunostaining (brown cells). (E) They were from
donor female subject (and therefore not from mouse host) as demon-
strated by absence of Y chromosome detected by FISH analysis only in
cancer cells from male donor (light green dots).
FIGURE 2. Binding trace graph (decay-corrected) for uptake of 99mTc-
anti-CD56 mAb to human NKs in vitro reaching maximum binding after
60 min. At this time point, radioactive medium was replaced with cold
PBS and retention studies were performed. Each point represents single
measurement on same petri dish over time.
1578 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 56 • No. 10 • October 2015
by Univ Studi Di Roma Library on January 3, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
chelator obtaining a high labeling efficiency and stability. In vivo,
in SCID mice lacking human NKs, the proposed radiopharmaceu-
tical showed typical characteristics of other radiolabeled mAbs but
with a shorter circulating half-life and high uptake in the liver and
at a lower extent in the kidneys. After reconstitution of mice with
human NKs, the biodistribution of the labeled antibody changed,
showing a lower circulating half-life and higher liver and spleen
activity due to specific binding to NKs homing in these tissues.
These data are in agreement with those reported by Rai et al.
(24) that hypothesized that either NKs could be resident in the liver
or the organ itself could be responsible for the metabolization of
both radiopharmaceutical and cells. In vivo targeting of Matrigel-
immobilized NKs reached the maximum T/B ratio at between 6 and
24 h, suggesting that this time frame is the best choice for imaging.
In our in vivo studies, we demonstrated a rapid infiltration of tumors
by NKs starting as early as 3 h after intravenous administration of
cells without any contamination from endogenous NKs, as revealed
by immunohistochemistry and FISH staining. We can therefore
speculate that murine NKs (present in SCID mice) do not efficiently
recognize and infiltrate human xenograft tumors. The number of
TINKs correlated positively with tumor size and with percentage
necrosis over time, highlighting a direct killing effect of TINKs on
the lesion and the full functionality of these cells. Imaging experi-
ments on mice bearing ARO xenografts demonstrated a clear uptake
of the radiopharmaceutical, with a T/B of 6.02 at 24 h. Moreover,
tumor size, together with number of TINKs, positively correlated
also with the radioactivity detected by ex vivo counting and by in
vivo high-resolution portable mini g camera imaging. This clearly
indicates that it is possible to image TINKs in vivo with 99mTc-
anti-CD56. Our study also opens the possibility of improving the
described imaging technique using a positron-emitting isotope.
Indeed, other attempts at imaging NKs have been reported in the
literature, including MR imaging (25), fluorescence and biolu-
minescence imaging (26), SPECT (27), and PET (28). No tech-
nique has emerged as superior to the others, but nuclear medicine
approaches have proven to be most promising for human studies.
To this aim, human NKs have been labeled ex vivo with 111In-
oxine and readministered to patients with metastatic melanoma (29).
Interesting but preliminary results were also reported for patients
with renal or colon carcinoma (30,31). Nevertheless, authors have
reported that 111In-oxine may have detrimental effects on NKs and is
rapidly released from labeled cells, thus increasing background ac-
tivity. Our approach overcomes these limitations and proved to be
suitable for NK imaging in vivo, with no toxicity to cells. A limi-
tation of our work is certainly the mouse model, which may not
reflect the situation in humans. Indeed, our SCID mice were recon-
stituted with a supraphysiologic amount of human NKs and they
rapidly infiltrated the human xenograft. In humans, the number of
NKs infiltrating a tumor, or its metastasis, may be much lower than
in our experiments, particularly under basal conditions. Many drugs
already commercially available may, however, significantly increase
the number of TINKs, thus allowing their in vivo detection.
CONCLUSION
This pilot study demonstrated that it is possible to efficiently
image NKs in vivo and their trafficking in human tumors implanted
in immune-deficient mice. Further studies are needed to confirm the
application of this technique to monitor the efficacy of different
therapeutic strategies aimed at increasing NK recruitment in tumors.
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